Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.47 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.44 |
| ▸ | CCR2 | P41597 | 2/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25683476 | 0.98 | CNR1 (0.46) | FAAHKDM4ETP53CYP3A4MAPT | |
| SCHEMBL27462713 | 0.86 | EPHX1 (0.52) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL20363209 | 0.84 | FAAH (0.48) | FAAHEPHX1CES2 | |
| SCHEMBL19882341 | 0.83 | KMT2A (0.46) | FAAHCNR1CCR2 | |
| SCHEMBL25680590 | 0.82 | CNR1 (0.35) | FAAHKDM4ETP53CYP3A4MAPT | |
| SCHEMBL20363242 | 0.82 | FAAH (0.47) | FAAHEPHX1CES2 | |
| SCHEMBL21018047 | 0.82 | CNR1 (0.48) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL21017765 | 0.82 | CNR1 (0.48) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL7884885 | 0.82 | CNR1 (0.48) | KDM4ETP53CYP3A4MAPTALOX15 | |
| SCHEMBL10897107 | 0.82 | CNR1 (0.48) | KDM4ETP53CYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023114198-A2 | METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | FAAH 2884/4885KDM4E 4570/4885TP53 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.